Financing channel feed – Endpoints News

Financing channel feed

Frazier backs MavuPharma’s $20M round, brings in heavyweight execs to lead

8 years ago

Doug Williams ups the ante at Codiak Bio to $168.5M in a drive to first human study

8 years ago

RA backs Medeor’s $57M round as researchers fast forward to PhIII

8 years ago

AstraZeneca teams with China-owned fund to launch a new biopharma drug development company

8 years ago

Six top biotech VCs take a look at the latest trends, and offer their thoughts on 2018

8 years ago

French upstart Step Pharma raises €8.6M, taking immunosuppressive drugs to the clinic

8 years ago

ScPharmaceuticals raises $90M in IPO with heart failure drug on deck

8 years ago

What's a successful failure? Atlas' Booth sounds taps for Merck-backed Quartet Medicine

8 years ago

Arsanis prices $40M IPO for infectious disease work

8 years ago

X4 raises $27M to take Sanofi’s old drug through pivotal trial

8 years ago

Johns Hopkins has $65M to spend on taking their drugs right up to human studies

8 years ago

$49M round; experienced team; A-list VCs — Inozyme launches with rare disease strategy and a yen for bigger things to come

8 years ago

Award-winning sepsis project gets $13M and a shot at reopening an R&D avenue as FDA pitches out old gold standard

8 years ago

San Diego’s stealthy Odonate surfaces with $173M IPO

8 years ago

ImmusanT scores a $40M round for PhII celiac study, with biotech vet Tom Daniel joining the board

8 years ago

Torque takes tumor tech out of stealth with $25M backing, new CEO

8 years ago

Neurodegeneration upstart Denali outlines $100M IPO for its growing clinical work

8 years ago

Google backs I/O startup Arcus in $107M deal

8 years ago

Bill Gates has a $100M and a 5-point strategy to end 15 years of failure in Alzheimer’s R&D

8 years ago

Hunting for early-stage life sciences bets, Partners Healthcare closes $171M for venture fund

8 years ago

Prepping PhIII for Soliris rival, Apellis rides a boisterous market to a $150M IPO

8 years ago

Eyeing Duchenne MD cure, The Column Group gambles $40M on CRISPR/Cas9 startup Exonics

8 years ago

German biotech InflaRx raises $100M in IPO

8 years ago

Amgen bets on stem cell company Fortuna Fix in $25M round

8 years ago

First page Previous page 134 135 136137138 139 140 Next page Last page